Celgene and IBM Watson Health ally on patient safety monitoring

Pharmaceutical Company Product News

Celgene has announced a new patient safety monitoring project to be developed in collaboration with IBM Watson Health.

The IBM Watson for Patient Safety offering will run on the Watson Health Cloud and will provide enhanced pharmacovigilance methods to collect, assess, monitor and report adverse drug reactions.

“Celgene and IBM Watson Health have announced a new collaboration aimed at improving patient safety monitoring standards.“

It will combine Watson's cognitive computing capabilities with Celgene's expertise in drug safety and risk management to create an outcome and evidence-based drug safety decision support system for life science companies.

This will facilitate the rapid collection, collation and automated analysis of high volumes of data from a range of sources, thereby enhancing pharmaceutical companies' understanding of safety issues and informing the risk/benefit profiles of new drugs.

John Freeman, corporate vice-president of global drug safety and risk management for Celgene, said: "The new offering we are co-developing will bring the cognitive computing power of Watson and its growing view of clinical, research and social health data to bear on this critical healthcare challenge."

Watson for Patient Safety will be developed in phases, with the first module anticipated within the next year.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news

Tags